Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “neutral” rating reiterated by research analysts at Cantor Fitzgerald in a research note issued on Tuesday, MarketBeat reports. They presently have a $40.00 price target on the biotechnology company’s stock, down from their prior price target of $166.00. Cantor Fitzgerald’s price objective points to a potential downside of 47.73% from the company’s current price.
SRPT has been the subject of several other reports. StockNews.com started coverage on Sarepta Therapeutics in a report on Thursday, October 5th. They issued a “hold” rating for the company. Mizuho restated a “buy” rating and issued a $160.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, September 26th. Needham & Company LLC reduced their target price on Sarepta Therapeutics from $185.00 to $82.00 and set a “buy” rating for the company in a report on Tuesday. Oppenheimer lowered Sarepta Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday. Finally, Morgan Stanley reduced their target price on Sarepta Therapeutics from $183.00 to $146.00 and set an “overweight” rating for the company in a report on Tuesday. Four investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $152.15.
Read Our Latest Report on SRPT
Sarepta Therapeutics Stock Performance
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) last issued its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.63) by $2.00. Sarepta Therapeutics had a negative net margin of 90.46% and a negative return on equity of 91.22%. The firm had revenue of $331.80 million during the quarter, compared to analysts’ expectations of $285.33 million. During the same period in the prior year, the company posted ($2.94) earnings per share. Sarepta Therapeutics’s revenue for the quarter was up 44.1% on a year-over-year basis. As a group, equities analysts anticipate that Sarepta Therapeutics will post -9.19 EPS for the current fiscal year.
Insider Activity
In other news, Director Michael Andrew Chambers acquired 34,867 shares of the stock in a transaction dated Thursday, August 10th. The shares were acquired at an average cost of $106.15 per share, for a total transaction of $3,701,132.05. Following the completion of the transaction, the director now owns 213,331 shares in the company, valued at approximately $22,645,085.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Michael Andrew Chambers acquired 34,867 shares of the stock in a transaction dated Thursday, August 10th. The shares were acquired at an average cost of $106.15 per share, for a total transaction of $3,701,132.05. Following the completion of the transaction, the director now owns 213,331 shares in the company, valued at approximately $22,645,085.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $106.72, for a total value of $1,600,800.00. Following the sale, the director now owns 20,994 shares in the company, valued at $2,240,479.68. The disclosure for this sale can be found here. 7.40% of the stock is currently owned by company insiders.
Institutional Trading of Sarepta Therapeutics
A number of large investors have recently bought and sold shares of SRPT. PNC Financial Services Group Inc. grew its position in Sarepta Therapeutics by 189.1% in the first quarter. PNC Financial Services Group Inc. now owns 5,784 shares of the biotechnology company’s stock valued at $452,000 after acquiring an additional 3,783 shares during the period. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Sarepta Therapeutics in the first quarter valued at $185,000. MetLife Investment Management LLC bought a new stake in Sarepta Therapeutics in the first quarter valued at $421,000. Great West Life Assurance Co. Can grew its position in Sarepta Therapeutics by 6.6% in the first quarter. Great West Life Assurance Co. Can now owns 4,541 shares of the biotechnology company’s stock valued at $377,000 after acquiring an additional 281 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in Sarepta Therapeutics by 12.3% in the first quarter. Dimensional Fund Advisors LP now owns 179,294 shares of the biotechnology company’s stock valued at $14,007,000 after acquiring an additional 19,660 shares during the period. 91.82% of the stock is currently owned by institutional investors.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene.
Read More
- Five stocks we like better than Sarepta Therapeutics
- Best Stocks Under $5.00
- First Solar, an affordable, high-quality green investment
- How to Invest in Social Media
- 5 Dow stocks to track during the market correction
- Your Comprehensive Guide to Investing in Bank Stocks
- Lean on these stocks during GDP expansion
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
